A federal court has agreed with plaintiff’s counsel in a recent ruling that warnings about the dangers of Avandia, a drug used to help manage Type II Diabetes, may have been inadequate, according to an article published in Lawyers USA.
After years of knowing the dangers, the FDA decided last May to pull Avandia from pharmaceutical shelves beginning in November. Research links Avandia to serious side effects such as pulmonary edema, heart attack and heart failure.
Drug manufacturer GlaxoSmithKline tried to dismiss several of the cases where the plaintiff took Avandia after its product labels were updated with revised warnings in both 2001 and 2001.
However, the court ruled that it was not a matter of law that the revised warnings adequately warned users of the drug’s risks, according to the article.
“In short, a reasonable jury could conclude that although the 2001 and 2007 labels warned about [congestive heart failure] risks, they did not do so specifically enough or directly enough,” the court said.
